10-Q: HI-GREAT Group Faces Mounting Losses, Going Concern Risk

HI-GREAT Group Holding Company reported a significant increase in net loss and declining sales for the first half of 2025, alongside critical internal control deficiencies and a going concern warning.

Summary

• HI-GREAT Group Holding Company, a development stage enterprise, reported a net loss of $35,982 for the six months ended June 30, 2025, a 25.3% increase from $28,710 in the prior year period.
• Sales decreased by 21.8% to $19,018 for the six months ended June 30, 2025, compared to $24,330 in the same period of 2024.
• Gross profit declined by 40.2% to $6,914 for the six months ended June 30, 2025, from $11,558 in the prior year.
• The company's cash balance was critically low at $222 as of June 30, 2025, down from $2,140 at December 31, 2024.
• Operating activities used $10,871 in cash for the six months ended June 30, 2025, a significant shift from $5,347 provided in the prior year period.
• An accumulated deficit of $928,776 was reported as of June 30, 2025, up from $892,794 at December 31, 2024.
• Management concluded that disclosure controls and procedures were not effective due to a lack of an audit committee and segregation of duties.
• The company has withdrawn CBD Oils from its business plan and is refocusing on an exclusive worldwide license for KRAS gene research and expanding into the cosmetic sector, alongside existing SellaCare organic longevity health supplements.
• Issued 2,500,000 shares of common stock for services during the period, including 1,500,000 shares to Madeline Choi and 1,000,000 shares to Globex Transfer, LLC.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial state with increasing losses, declining revenue, minimal cash, and a significant accumulated deficit. The explicit 'going concern' warning and identified material weaknesses in internal controls are major red flags, overshadowing any strategic pivots.

Positives

• Secured an exclusive worldwide license agreement pertaining to the KRAS gene, a significant driver mutation in various cancers, indicating a strategic pivot into a potentially high-impact area.
• Plans to diversify into the lucrative cosmetic sector, aiming for a sustainable revenue platform.
• Successfully issued 2,500,000 shares of common stock for services provided by Madeline Choi and Globex Transfer, LLC, demonstrating an ability to compensate vendors without immediate cash outlay.

Negatives

• Net loss increased by 25.3% to $35,982 for the six months ended June 30, 2025, compared to the same period in 2024.
• Sales decreased by 21.8% to $19,018 for the six months ended June 30, 2025, indicating a significant decline in revenue generation.
• Gross profit fell by 40.2% to $6,914 for the six months ended June 30, 2025, reflecting reduced profitability from sales.
• Cash balance is critically low at $222 as of June 30, 2025, raising immediate liquidity concerns.
• Operating activities consumed $10,871 in cash for the six months ended June 30, 2025, a negative shift from cash provided in the prior year.
• Accumulated deficit grew to $928,776, highlighting a history of unprofitability and erosion of shareholder equity.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses, specifically the lack of an audit committee and segregation of duties, posing significant governance risks.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient revenues to cover operating costs and dependence on debt and equity financing.
• There is no assurance that the company will be able to raise additional equity capital or successfully develop and commercialize its products, including those related to the KRAS gene.
• The COVID-19 pandemic, while having a minimal impact on day-to-day operations to date, could still affect efforts to enter into business combinations or impact economic conditions.
• Ineffective disclosure controls and procedures, stemming from a lack of an audit committee and segregation of duties, increase the risk of financial misstatement and lack of oversight.

Future Outlook

The company is refocusing its business plan to include an exclusive global licensing agreement for the KRAS gene, which is frequently mutated in various cancers. It will continue to market and distribute SellaCare, Inc.'s organic longevity health supplements and plans to expand into the cosmetic sector as a strategic component for sustainable revenue. Management is actively working to raise additional funding to support operations.

Management Comments

• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• While management believes it will be successful in its capital formation and planned operating activities, there can be no assurance that the company will be able to raise additional equity capital or be successful in the development and commercialization of its products.
• Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the quarterly period ended June 30, 2025, due to a lack of an audit committee and segregation of duties.

Industry Context

As a development stage enterprise, HI-GREAT Group Holding Company operates with minimal established revenue streams and significant reliance on external financing. Its pivot from CBD oils to KRAS gene research and cosmetics indicates an attempt to enter higher-growth or more specialized markets, potentially seeking a more viable business model beyond its current agritourism and herbal supplement activities. The challenges faced, such as declining sales and substantial losses, are common for companies in early development but are exacerbated by the identified governance weaknesses.

Comparison to Industry Standards

• The company's financial performance, characterized by increasing net losses and declining sales, falls significantly below industry standards for established companies, aligning more with the high-risk profile of a development-stage enterprise.
• The critically low cash balance of $222 and negative cash flow from operations are indicative of severe liquidity issues, which are concerning even for development-stage companies that typically burn cash, as it suggests an inability to sustain operations without immediate external capital.
• The identified material weaknesses in corporate governance, specifically the lack of an audit committee and segregation of duties, are below acceptable standards for publicly traded companies, regardless of size, and raise serious concerns about financial oversight and internal controls compared to peers like smaller biotech firms or consumer product startups that typically strive for robust governance structures to attract investment.

Corporate Governance

Related Party Transactions

• Licensing agreement with SellaCare, Inc. (controlled by the company's majority shareholder) requiring payment of 25% of gross revenues or a minimum of $1,000, with $166,977 accrued as of June 30, 2025.
• Land lease agreement with Sella Property, LLC (an entity controlled by the company's majority shareholder) for $30,000 in annual installments, which matured on March 16, 2025.
• The company sells herbal supplements purchased directly from SellaCare, Inc. using the SellaCare brand.

Stakeholder Impact

• Shareholders face significant risk of further value erosion due to ongoing losses, the going concern warning, and ineffective internal controls. Potential dilution from future capital raises is also a concern.
• Creditors face increased risk due to the company's precarious financial position, high accumulated deficit, and critically low cash balance.
• Employees may experience uncertainty regarding job security and the company's long-term viability given the financial distress and dependence on external funding.
• Suppliers and vendors may face increased risk of delayed payments or non-payment due to the company's liquidity issues and negative cash flow from operations.

Next Steps

• Management will continue efforts to raise additional funding.
• Development and commercialization of products related to the exclusive KRAS gene license.
• Expansion into the cosmetic sector as a sustainable revenue platform.

Key Dates

Recommendation

The company exhibits severe financial distress, including increasing net losses, declining sales, negative operating cash flow, and a critically low cash balance. The explicit 'going concern' warning, coupled with identified material weaknesses in internal controls (lack of an audit committee and segregation of duties), indicates fundamental operational and governance issues. While strategic pivots into KRAS gene research and cosmetics are mentioned, the company's current financial state and lack of effective controls present an exceptionally high-risk profile, making it unsuitable for investment.

Keywords

KRAS gene, SellaCare, herbal supplements, cosmetics, agritourism, development stage, SEC filing, 10-Q, financial results, corporate governance, related party transactions, going concern